Company Overview and News

1
Timberline Resources Provides Exploration Update on Windfall and Lookout Mountain Projects at Its Eureka Property in Nevada

2018-07-10 accesswire
COUER D'ALENE, ID / ACCESSWIRE / July 10, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announces an exploration update on its 23-square mile Eureka property (Figure 1) in Nevada's prolific Battle Mountain - Eureka gold trend. At the Windfall project, Timberline's exploration is focused on additional drilling to support development of an initial open-pittable oxide resource estimate.
ABX MUX.RTWI MUX MALRY TLRS TLR MALRF MUX MIN ABX

43
Timberline Resources Announces Board Changes and Adds Nevada Battle Mountain Exploration Expertise

2018-06-25 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / June 25, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") is pleased to announce that Mr. Donald J. McDowell and Mr. David C. Mathewson have joined the Company's Board of Directors.
APPPF ABX MUX.RTWI CCCCF MUX TLRS TLR GSV MUX ABX CCC

43
Timberline Resources Announces Gold and Copper Assay Results for the Elder Creek Project, Battle Mountain District, Nevada

2018-06-18 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / June 18, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that geologic mapping, surface sampling, and an aeromagnetic survey have defined a large porphyry copper target on the Elder Creek project in the Battle Mountain District of Nevada. Timberline has entered into a purchase and sale agreement with America's Gold Exploration Inc.
ABX MUX.RTWI MUX TLRS TLR MUX ABX

43
Timberline Resources Announces High-Grade Gold and Silver Assay Results from the Oswego Trend, Eureka Project, Nevada

2018-06-12 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / June 12, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that results of surface rock chip sampling and geologic mapping have defined new, high-grade, gold exploration targets along the Oswego trend on its 23 square-mile Eureka property in Northern Nevada. The Oswego trend, which extends 5 km north-south, includes high-grade gold at the Road-Cut target, high-grade silver and gold at the Geddes- Bertrand target, and numerous additional untested targets.
ABX MUX.RTWI MUX TLRS TLR MUX ABX

5
Timberline Announces Second Quarter 2018 Financial Results

2018-05-12 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / May 11, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) (''Timberline'' or the ''Company'') today announced consolidated financial results for its second fiscal year 2018 quarter which ended March 31, 2018. A summary of selected financial results is presented in the following table:
TLRS TLR

5
Timberline Resources Closes Private Placement Financing

2018-05-09 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / May 9, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced that it has received final approval from the TSX Venture Exchange for its private placement and has closed its previously announced non-brokered private placement (the "Offering").
TLRS TLR

5
Timberline Resources Announces Private Placement Offering

2018-05-08 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / May 7, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that it has initiated a non-brokered US$500,000 private placement offering of Units of the Company at a price of US$0.08 per Unit, with an option to increase the offering by up to 20%, solely to persons who qualify as accredited investors (the "Offering") under Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended (the "Securities Act").
TLRS TLR

43
Timberline Resources Agrees to Acquire Battle Mountain Gold-Copper Property Interests

2018-04-23 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / April 23, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that it has agreed to acquire ownership interests in two Nevada gold-copper mineral properties located in the world-class Battle Mountain mining district from Americas Gold Exploration, Inc. ("AGEI").
ABX MUX.RTWI MUX TLRS TLR MUX ABX

9
Timberline Resources Re-initiates Eureka Project Exploration and Relinquishes Talapoosa Property Option

2018-04-03 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / April 3, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announces that it is refocusing its exploration efforts on advancing the Windfall and Lookout Mountain projects at its Eureka property, concurrent with relinquishing its option to acquire the Talapoosa project. Eureka is a district-scale exploration property in Nevada's prolific Battle Mountain - Eureka gold trend that hosts numerous world-class gold deposits.
MALRY TLRS TLR MALRF MIN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

47m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...